Based on the prescription drug sales in the previous year i.e., 2020, the annual list of top 50 biopharma companies was published by the Pharmaceutical Executive earlier in June. The infographic below lists the top 8 of these biopharma companies and according to it, Roche once again takes a bow with the higher number of Rx Sales and R&D Spend i.e., $47.5 billion and $11.3 billion, respectively.
The companies top seller drugs include MS drug Ocrevus and cancer medication Avastin. In addition, the incredible sales of some newly launched drugs by the company including, Hemlibra for hemophilia, Kadcyla and Perjeta for cancer, and Tecentriq also added to its overall sales.
This is the second consecutive year when Roche topped the ranking, overtaking Pfizer, the previous front-runner. However, Pfizer’s return to the first position is highly expected in 2021 due to its significant role in the pharmaceutical market after the invention of Covid-19 vaccines.
One of the major reasons why Roche’s market capped was bolstered in 2020 is its active part in the Covid-19 diagnostic testing. Despite being the fastest riser in the Rx Sales and leader of the annual ranking, the Illinois-based AbbVie company didn’t market even a single Covid-19 related product.
Novartis, a Swiss-based biopharma company holds the second position in prescription sales which is very close to Roche’s i.e., $47.2 billion. Its top sellers include Entresto, a heart failure drug, and MS medication Gilenya.
In terms of R&D Spend, another very prominent company, and a successful Covid-19 vaccine developer, Johnsons and Johnsons hold the second position.
Infographic by: Statista.com
